Special Warning : אזהרת שימוש

4.4   Special warnings and precautions for use

Monitoring
After the initiation period, cholestanol, urine bile alcohols and liver function should be determined annually, at a minimum, and the dose adjusted accordingly (see section 4.2). Additional or more frequent investigations may need to be undertaken to monitor therapy during periods of fast growth, concomitant disease and pregnancy (see section 4.6).

Co-administration of chenodeoxycholic acid with other medicinal products Co-administration with ciclosporin, sirolimus, phenobarital is not recommended, see section 4.5 for further details.

Colestipol or antacid medicinal products containing aluminium hydroxide and/or smectite should be taken either 2 hours before or after taking Chenodeoxycholic acid Leadiant, see section 4.5 for further details.
Chenodeoxycholic acid Leadiant should be taken either one hour before cholestyramine or 4-6 hours after, see section 4.5 for further details.


Co-administration with oral contraceptives is not recommended, see section 4.5 for further details.
Women of childbearing potential should use an effective method of contraception, see section 4.6 for further details.

Effects on Driving

4.7   Effects on ability to drive and use machines

Chenodeoxycholic acid Leadiant has no or negligible influence on the ability to drive and use machines.